Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

Multidisciplinary Treatment for GIST

Insights From: Robert Hans Ingemar Andtbacka, MD, CM, Huntsman Cancer Institute ; Anthony P. Conley, MD, The University of Texas MD Anderson Cancer CenterSyma Iqbal, MD, UCS Norris Comprehensive Cancer Center and Hospital
Published: Monday, Dec 21, 2015


Gastrointestinal stromal tumors (GISTs) are relatively rare, requiring a comprehensive knowledge base of various experts in order to provide patients with the best possible care, comments Syma Iqbal, MD. The multidisciplinary approach should include gastroenterologists who are experienced in identifying these tumors, radiologists who are skilled in assessing the density of the lesions on the scans, pathologists who are savvy at knowing what markers to look for, and surgeons who are familiar with surgical techniques used to remove these tumors.

The response rate to the tyrosine kinase inhibitor imatinib for patients with advanced or unresectable GIST is approximately 50%, states Iqbal. Imatinib can be administered in patients who are ineligible for surgical resection in order to shrink the tumor enough so that surgery becomes possible.

There is no clear data regarding the optimal duration of neoadjuvant imatinib, explains Iqbal, noting that patients tend to have responses anywhere from 6 to 12 months following treatment initiation. Tumors may continue to shrink beyond this time point. General guidelines recommend intervening when the patient becomes surgically resectable rather than waiting for maximum response.
Slider Left
Slider Right


Gastrointestinal stromal tumors (GISTs) are relatively rare, requiring a comprehensive knowledge base of various experts in order to provide patients with the best possible care, comments Syma Iqbal, MD. The multidisciplinary approach should include gastroenterologists who are experienced in identifying these tumors, radiologists who are skilled in assessing the density of the lesions on the scans, pathologists who are savvy at knowing what markers to look for, and surgeons who are familiar with surgical techniques used to remove these tumors.

The response rate to the tyrosine kinase inhibitor imatinib for patients with advanced or unresectable GIST is approximately 50%, states Iqbal. Imatinib can be administered in patients who are ineligible for surgical resection in order to shrink the tumor enough so that surgery becomes possible.

There is no clear data regarding the optimal duration of neoadjuvant imatinib, explains Iqbal, noting that patients tend to have responses anywhere from 6 to 12 months following treatment initiation. Tumors may continue to shrink beyond this time point. General guidelines recommend intervening when the patient becomes surgically resectable rather than waiting for maximum response.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x